B Cell News and Research

RSS

CytRx begins aldoxorubicin Phase 2b clinical trial in patients with extensive-stage SCLC

CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, today announced the initiation of a global Phase 2b clinical trial evaluating aldoxorubicin compared to topotecan in subjects with extensive-stage small cell lung cancer (SCLC) who have relapsed or were refractory to prior chemotherapy.

30 Sep 2014

Researchers uncover molecular interaction between key proteins in cell division

Researchers from Guillermo Montoya's team at the Spanish National Cancer Research Centre (CNIO), in collaboration with Isabelle Vernos' Group from the Centre for Genomic Regulation (CRG), have uncovered the molecular interaction between TACC3 and chTOG, key proteins in forming the internal cellular framework that enables and sustains cell division.

30 Sep 2014

Pemetrexed/docetaxel with cisplatin achieve similar progression-free survival in NSCLC patients

The first direct comparison of treating non-squamous lung cancer with either pemetrexed or docetaxel in addition to cisplatin has shown that the two combinations achieve similar progression-free survival, although docetaxel was associated with more frequent adverse events.

30 Sep 2014

Research: Gut bacteria may cause animals to gain weight

A species of gut bacteria called Clostridium ramosum, coupled with a high-fat diet, may cause animals to gain weight. The work is published this week in mBio-, the online open-access journal of the American Society for Microbiology.

30 Sep 2014

Research!America to recognize distinguished research advocates with Advocacy Awards

Research!America's 19th annual Advocacy Awards will honor distinguished research advocates who are trailblazers in advancing medical progress to improve the health and economic security of our nation. The event will take place on Wednesday, March 11, 2015, at the Andrew W. Mellon Auditorium in Washington, DC.

30 Sep 2014

Researchers explain how molecular structure of the heart muscle changes in heart failure

In a new study published in Proceedings of the National Academy of Sciences USA, researchers at the University of Alberta's Faculty of Medicine & Dentistry have explained how the function of a key protein in the heart changes in heart failure.

30 Sep 2014

PD-L1 protein could be a potential immunotherapy target for malignant pleural mesothelioma

Treating patients with high-dose radiotherapy after chemotherapy and surgery for malignant pleural mesothelioma does not achieve improvements in local relapse and overall survival, according to data from a prospective randomized phase II trial presented at ESMO 2014 Congress in Madrid.

30 Sep 2014

Combination therapy achieves greater progression-free survival, response rates in melanoma

Combination therapy with both BRAF inhibitor vemurafenib and MEK inhibitor cobimetinib achieves greater progression-free survival and response rates than vemurafenib plus placebo in BRAF-mutation positive melanoma, according to phase III data presented at the ESMO 2014 Congress in Madrid, Spain.

30 Sep 2014

New approach to solve global challenges in food security, emerging diseases and biodiversity loss

Solving global challenges in food security, emerging diseases and biodiversity loss requires evolutionary thinking, argues a new study published online in Science Express that was co-authored by Bruce Tabashnik of the University of Arizona College of Agriculture and Life Sciences.

30 Sep 2014

Abbvie announces multiple study results of veliparib investigational compound in NSCLC patients

AbbVie released interim results from an ongoing Phase 2 study of its investigational compound veliparib in combination with chemotherapy, which showed a 35 percent improvement (P-value=0.14) in progression-free survival (PFS) and a 30 percent improvement (P-value=0.21) in overall survival (OS) in patients with previously untreated metastatic or advanced non-small cell lung cancer (NSCLC).

30 Sep 2014

Targeted combination drug therapy can extend life, halt disease in metastatic melanoma patients

A world-first study in today's New England Journal of Medicine heralds the efficacy of a targeted combination drug therapy after reporting major declines in the risk of disease progression and death in people with metastatic melanoma.

29 Sep 2014

Dabrafenib shows significant anti-tumour activity in BRAF V600E mutant non-small cell lung cancer

The BRAF inhibitor dabrafenib has significant anti-tumour activity in patients with advanced BRAF V600E mutant non-small cell lung cancer whose disease has progressed after chemotherapy, according to phase II data presented at the ESMO 2014 Congress in Madrid, Spain.

29 Sep 2014

Scientists show how individual neurons in the human brain react to morphed faces

An international team of scientists, involving Professor Rodrigo Quian Quiroga, director of the Centre for Systems Neuroscience and Head of Bioengineering at the University of Leicester, has shown how individual neurons in the human brain react to ambiguous morphed faces.

29 Sep 2014

Aptose joins Beat AML research collaboration

Aptose Biosciences Inc., a clinical-stage company developing new therapeutics and molecular diagnostics that target the underlying mechanisms of cancer, the Knight Cancer Institute at Oregon Health & Science University and The Leukemia & Lymphoma Society today announced that Aptose has joined the Beat AML collaboration.

29 Sep 2014

Cediranib combined with chemotherapy improves survival in recurrent cervical cancer

For patients with cervical cancer that has recurred after treatment or has spread elsewhere in the body, adding the experimental drug cediranib to standard chemotherapy improves tumour shrinkage and adds a modest improvement in progression-free survival, researchers report at the ESMO 2014 Congress in Madrid.

29 Sep 2014

Scientists reveal that human brain can trigger random behavior

Many of the choices we make are informed by experiences we've had in the past. But occasionally we're better off abandoning those lessons and exploring a new situation unfettered by past experiences.

29 Sep 2014

FDA grants multiple Orphan Drug Designations for CytRx's aldoxorubicin

CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, today announced that the U.S. Food and Drug Administration has granted multiple Orphan Drug Designations for the Company's lead drug candidate, aldoxorubicin, in three indications: glioblastoma multiforme (GBM), small cell lung cancer and ovarian cancer.

29 Sep 2014

Scientists discover mechanism that resists cancer drugs in estrogen-positive breast cancer

Scientists have discovered a previously unknown mechanism by which estrogen prepares cells to divide, grow and, in the case of estrogen-positive breast cancers, resist cancer drugs. The researchers say the work reveals new targets for breast cancer therapy and will help doctors predict which patients need the most aggressive treatment.

29 Sep 2014

Researchers create new Cas9 animal model for in vivo genome editing experiments

Researchers from the Broad Institute and Massachusetts Institute of Technology have created a new mouse model to simplify application of the CRISPR-Cas9 system for in vivo genome editing experiments.

29 Sep 2014

Fecal microbiota transplantation officially recommended for effective treatment of C. difficile infection

The transplantation of faecal microbiota from a healthy donor has been shown in recent clinical studies to be a safe and highly effective treatment for recurrent Clostridium difficile (C. difficile) infection and is now recommended in European treatment guidelines.

29 Sep 2014

B Cell News and Research

CytRx begins aldoxorubicin Phase 2b clinical trial in patients with extensive-stage SCLC

Researchers uncover molecular interaction between key proteins in cell division

Pemetrexed/docetaxel with cisplatin achieve similar progression-free survival in NSCLC patients

Research: Gut bacteria may cause animals to gain weight

Research!America to recognize distinguished research advocates with Advocacy Awards

Researchers explain how molecular structure of the heart muscle changes in heart failure

PD-L1 protein could be a potential immunotherapy target for malignant pleural mesothelioma

Combination therapy achieves greater progression-free survival, response rates in melanoma

New approach to solve global challenges in food security, emerging diseases and biodiversity loss

Abbvie announces multiple study results of veliparib investigational compound in NSCLC patients

Targeted combination drug therapy can extend life, halt disease in metastatic melanoma patients

Dabrafenib shows significant anti-tumour activity in BRAF V600E mutant non-small cell lung cancer

Scientists show how individual neurons in the human brain react to morphed faces

Aptose joins Beat AML research collaboration

Cediranib combined with chemotherapy improves survival in recurrent cervical cancer

Scientists reveal that human brain can trigger random behavior

FDA grants multiple Orphan Drug Designations for CytRx's aldoxorubicin

Scientists discover mechanism that resists cancer drugs in estrogen-positive breast cancer

Researchers create new Cas9 animal model for in vivo genome editing experiments

Fecal microbiota transplantation officially recommended for effective treatment of C. difficile infection

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News